CCL17 and interstitial lung disease: There were a trend towards higher serum levels of CCL17 in patients with ILD progression within 1 year than in those without (P = 0.060) and a trend towards a higher proportion of patients with ILD progression within 1 year in the CCL17 high group than in the CCL17 low group (27.27% vs. 8.11%; P = 0.055) (Fig. 5D and E).